TRENDING :  Market Movers  |  Top 50   AAPL (0%)    TSLA (0%)    TVIX (0%)    RIOT (0%)    QURE (0%)    QQQ (0%)    QCOM (0%)    PSTG (0%)    PEI (0%)    PAH (0%)    MCD (0%)    KO (0%)    JPM (0%)    IVC (0%)    IMDZ (0%)    GS (0%)    GOOGL (0%)    FDX (0%)    FCEL (0%)    FB (0%)    EA (0%)    CRM (0%)    CBS (0%)    BILI (0%)    BIDU (0%)

 ALKS - Alkermes plc

$32.57 [0][0%]

Next Earnings



Trade Idea »


Quarterly Rating Chart


1=Strong Buy, 2=Buy, 3=Hold, 4=Underperform, 5=Sell
Price Targets
High $31.00
Low $26.00
Average $28.50
Current $32.57

CompanyAnalyst NamePT ActionActionRatingTargetDate
Goldman SachsLowersDowngradesSell$26.0012/19/18
Credit SuisseVamil DivanLowersDowngradesUnderperform$31.0012/13/18
*Last 90 days


No recommendations found.

This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.



Biotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & More

As we approach the tail end o f earnings results regular pipeline updates and data read outs take centerstage in the biotech sector Key among those include Intercept ICPT which surges on the back of positive data from the phase III trial on NASH drug and Vertex which too reports

Consumer Sector Update for 02/19/2019: MOR,CNDT,ICPT,CLVS,ALKS

Top Health Care StocksTop Health Care Stocks JNJ 0 26 JNJ 0 26 PFE 0 84 PFE 0 84 ABT 0 32 ABT 0 32 MRK 0 40 MRK 0 40 AMGN 0 37 AMGN 0 37 Health care stocks were narrowly lower this afternoon including a 0 1 drop for the NYSE Health Care Index in late trade Shares of health

Tuesday's ETF with Unusual Volume: PBE

The Invesco Dynamic Biotechnology amp Genome ETF PBE is seeing unusually high volume in afternoon trading Tuesday with over 222 000 shares traded versus three month average volume of about 25 000 Shares of PBE were off about 0 8 on the day Components of that ETF with the

Health Care Sector Update for 02/19/2019: CNDT,ICPT,CLVS,ALKS

Top Health Care StocksTop Health Care Stocks JNJ 0 38 JNJ 0 38 PFE 0 79 PFE 0 79 ABT 0 26 ABT 0 26 MRK 0 43 MRK 0 43 AMGN 0 46 AMGN 0 46 Health care stocks were narrowly lower this afternoon including a 0 3 loss for the NYSE Health Care Index in recent trade Shares of health

Alkermes Breaks $1 Billion

Alkermes NASDAQ ALKS 160 had 2018 revenue that came in at over 1 billion the level that s typically set as a blockbuster Of course it took the biotech a couple of drugs and royalties on a handful of others to get to that level but it s a solid start as the company continues

We Did The Math EQWM Can Go To $55

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the

Alkermes (ALKS) Q4 Earnings & Revenues Surpass Estimates

Alkermes plc 160 ALKS reported adjusted earnings of 34 cents per share in the fourth quarter of 2018 outperforming the Zacks Consensus Estimate of a loss of 6 cents The bottom line also exceeded the adjusted earnings of 31 cents recorded in the year ago quarter The company s revenues

Alkermes Plc (ALKS) Q4 2018 Earnings Conference Call Transcript

Image source The Motley Fool Alkermes Plc NASDAQ ALKS Q4 2018 Earnings Conference Call Feb 14 2019 8 30 a m ET Contents Prepared Remarks Questions and Answers Call Participants Prepared Remarks Operator

Alkermes (ALKS) Q4 Earnings and Revenues Beat Estimates

Alkermes ALKS came out with quarterly earnings of 0 34 per share beating the Zacks Consensus Estimate of a loss of 0 06 per share This compares to earnings of 0 31 per share a year ago These figures are adjusted for non recurring items This quarterly report represents an earnings

The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO

For Immediate Release Chicago IL February 7 2019 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog

Notable Wednesday Option Activity: ALKS, DMRC, INGN

Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Alkermes plc Symbol ALKS where a total of 10 799 contracts have traded so far representing approximately 1 1 million underlying shares That amounts to about 143 5 of ALKS s

Analysts Estimate Alkermes (ALKS) to Report a Decline in Earnings: What to Look Out for

Alkermes ALKS is expected to deliver a year over year decline in earnings on lower revenues when i t report s results for the quarter ended December 2018 This widely known consensus outlook gives a good sense of the company s earnings picture but how the actual results compare to

Biotech Stock Roundup: Celgene Tops in Q4, Gilead Disappoints, ALKS & AVEO Sink

Earnings took centerstage for the biotech sector this week with quite a few bigwigs like Gilead Sciences GILD Vertex Pharmaceuticals VRTX and Celgene CELG coming up with fourth quarter results Apart from these regular pipeline updates and data read outs were also in the

Alkermes Sinks as FDA Refuses to Approve Depression Drug

Alkermes Plc ALKS announced that the FDA has issued a Complete Response Letter CRL related to its new drug application NDA for ALKS 5461 The NDA sought approval for the candidate as an adjunctive treatment of major depressive disorder MDD The regulatory authority refused

Biogen Looks to 2020

Biogen NASDAQ BIIB posted solid fourth quarter earnings on Tuesday but lackluster 2019 revenue guidance leaves investors twiddling their thumbs waiting for growth from the next big hit from the biotech s drug pipeline Biogen results The raw